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ABSTRACT 
 
 The high prevalence of Type 2 diabetes (T2D) has brought it to the foreground of 
attention in the scientific community. SERCA3-ATPases help regulate intracellular Ca2+ 
levels, which are critical for maintaining normal insulin secretion and thus glucose 
homeostasis. SERCA3 down-regulation has been observed in T2D patients, but it is 
currently unclear whether this down-regulation is a cause or consequence of T2D. To 
investigate the role of the SERCA3 pathway in diabetes, experiments in this project 
knocked down the SERCA3 gene in EndoC-βH1 human pancreatic islets derived from 
diabetic patients and from pancreatic beta cells derived and differentiated from human stem 
cells. This was done in order to determine if the knockdowns would affect insulin secretion 
or induce physiological changes in pancreatic beta cells. Western blot analysis and 
fluorescence intensities were used to determine relative protein expression. qPCR 
experiments were performed to determine mRNA levels. In addition, the fluorescence 
intensities of SERCA3 and insulin in healthy and T2D pancreatic islets were quantitated. 
Protein levels of insulin and SERCA3 were significantly lower in diabetic pancreatic islet 
samples compared to healthy controls. Two-tailed t-tests for SERCA3 and insulin down-
regulation gave p values of 2.01 x 10-8 and 6.26 x 10-3, respectively. Western analysis of 
the SERCA3 and insulin levels in healthy and T2D individuals also confirmed 
downregulation of both proteins in T2D islets compared to healthy islets as observed by 
immunofluorescence. Adenovirus-shRNA-induced knockdown of SERCA3 expression 
was validated at both the mRNA (q-RT-PCR) and protein (Western blots) levels, but those 
cells have not yet been assayed for the potential effects of insulin secretion.  Overall, the 
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results of this project indicate that the SERCA3 pathway is important for optimal insulin 
secretion. 
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 1 
BACKGROUND 
 
Overview of Diabetes 
        Diabetes is a glucose dysregulation disease that has become a serious global health 
problem affecting approximately 8% of the adult population worldwide, and is currently at 
the foreground of attention in the scientific community (Gilon et al., 2014). The 
development of type 2 diabetes (T2D) is of special heightened concern, as it occurs 
approximately 20 times more frequently than type 1 diabetes (T1D) (Gilon et al., 2014). 
While T1D causes self-destruction of insulin-producing cells in the body, T2D develops 
when beta cells fail to secrete enough insulin to compensate for relative insulin deficiency. 
T2D is the more prevalent type, with 285 million cases recorded worldwide as of 2010 
(Williams, 2011). T2D has a genetic risk, but dietary habits and environmental factors also 
influence this disorder. Only about 1-2% of all T2D cases are caused by a single gene 
mutation (Gilon et al., 2014). T2D patients usually have insulin resistance, a lack of 
response to insulin, or lack insulin altogether, and tend to develop hyperglycemia. 
Although much research has focused on mechanisms of insulin secretion, factors leading 
to insulin insensitivity are not fully understood. For instance, the exact mechanism of how 
beta cells fail to secrete enough insulin is unknown, or why peripheral tissues become 
insulin insensitive. 
 
Insulin and Glucagon Signal Transduction Pathways 
The human endocrine system consists of various glands that secrete hormones into 
the circulatory system to interact with target organs (Williams, 2011).  The system 
functions to help maintain homeostasis in the body, and includes a variety of hormones 
such as testosterone, estrogen, insulin, glucagon, and epinephrine. Hormones help regulate 
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every essential function in the body, and are paired with alternative hormones to check and 
balance the function of the first.  The hormones often bind receptors present on the target 
tissues to initiate signaling pathways that alter cell function. 
With respect to diabetes, the main hormones of interest that help regulate glucose 
homeostasis are insulin, glucagon, and somatostatin.  Insulin is the body’s only hormone 
for lowering serum glucose levels.  Following the ingestion of a meal, glucose levels 
increase in the blood.  Insulin is secreted from the pancreatic β-cells into the bloodstream 
and binds to insulin receptors present on target tissues.  The binding of insulin to its target 
receptor (Figure-1, blue receptor, right side) initiates a signaling pathway(s) to upregulate 
glucose transporters (GLUT) (red receptor, left side) to the cell surface.  The GLUT’s bind 
serum glucose and transport it inside the cell to participate in glucose metabolism.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1:  Diagram of Insulin Receptor Signal Transduction Pathways.  Shown are the major 
pathways known to be activated by the binding of insulin to its receptor (blue receptor, right side), 
including the Ras/MAP kinase pathway (right side blue box), PI(3)K/AKT pathway (left side, blue 
box), and Cbl/CAP/TC10 pathway (orange and green proteins shown near the 
membrane).  Diagram is from Saltiel and Kahn (2001). 
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The up-regulation of GLUT in response to insulin is one of the best characterized 
cell signaling pathways.  The binding of insulin to its receptor induces the phosphorylation 
of cellular proteins, such as members of the insulin receptor substrate (IRS) family (red, 
diagram center), Shc (purple, diagram right), and Cbl (orange, diagram center). These 
phosphorylated proteins then activate a diverse series of signaling pathways, including the 
PI(3)K and Akt kinases (left side, blue box), Ras and the MAP kinase cascade (right side, 
blue box), and the Cbl/CAP/TC10 pathway (green and orange proteins shown immediately 
beneath the cell membrane). These pathways act together to regulate glucose, lipid, and 
protein metabolism. 
The regulation of insulin secretion from the pancreas is a complex process affected 
by a variety of stimuli including nutrients, hormones, neurotransmitters, and drugs 
(Rorsman and Braun, 2013). Insulin is produced and released from pancreatic β-cells.  The 
main trigger for insulin secretion is elevated serum glucose, which induces a biphasic 
pattern of insulin release. The first phase involves a rapid release of insulin within minutes 
of exposure to elevated glucose, followed by a more extended second phase of insulin 
release.  The first phase of insulin secretion appears to be lost in some T2D patients, leading 
to diminished insulin secretion and hyperglycemia.  Although scientists are still 
researching this complex homeostatic process, the main steps (Figure-2) are believed to 
include several processes: 1) the transport of glucose inside pancreatic β-cells using 
receptor GLUT-2, 2) cellular metabolism of the glucose to ATP using glycolysis and the 
TCA cycle, 3) the elevation of the ratio of ATP to ADP which induces closure of cell-
surface ATP-sensitive K+ (KATP) channels, leading to cell membrane depolarization, 4) 
the opening of cell surface voltage-dependent Ca2+ channels (VDCC) allowing Ca2+ to 
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increase in the cell (Gilon et al., 2014), and 5) increased insulin exocytosis triggered by 
elevated cytoplasmic Ca2+ levels. 
 
 
Figure-2: Diagram of the Main Steps Controlling Insulin Secretion from a Pancreatic Beta 
Cell.  Shown in the diagram is the entrance of glucose into the cell using a glucose transporter 
(purple receptor), the metabolic production of ATP from the glucose, closure of the ATP-sensitive 
K+ channel (green receptor), membrane depolarization, the flow of Ca2+ into the cell via a calcium 
channel, activation of Ca2+ dependent phospholipid protein kinase, and exocytosis of insulin 
granules (diagram right side). (http://www.medicinehack.com/2011/08/insulin-secretion-local-
regulation.html) 
 
 
        Glucagon is a hormone involved in glucose homeostasis. Glucagon is produced in 
pancreatic alpha islet cells and results in the storage of glucose in the liver as glycogen. 
Once stored, glycogen can be converted back into glucose to stimulate insulin activity. The 
reintroduction of glucose can also raise blood sugar levels during periods of starvation. 
Somatostatin, produced in pancreatic delta islet cells, balances the function of glucagon by 
inhibiting the release of glucagon from pancreatic alpha cells (Gilon et al., 2014). 
Glucagon, somatostatin, and insulin work in conjunction to maintain constant blood sugar 
levels throughout the body. Dysregulation of any of these hormones results in 
dysregulation of glucose homeostasis. 
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Alteration of Cell Signaling in Type-2 Diabetes 
Disruption of any of the homeostatic pathways described above can result in 
glucose dysregulation and diabetes.  Scientists are still investigating which pathways result 
in T2D, but several key processes are thought to be involved: 1) dysregulation of cell 
growth pathways leading to a lower number of pancreatic alpha/beta cells, resulting in 
lower insulin secretion, 2) disruption of the insulin signaling pathways, leading to insulin 
resistance and diminished GLUT up-regulation, and 3) disruption of the Ca2+ signaling in 
pancreatic cells, leading to reduced insulin secretion.   
Cell proliferation pathways are important for cell differentiation and, if 
dysregulated, may result in diseases, such as T2D. For example, Neurogenin (Ngn) is a 
transcription factor which acts upstream in the NeuroD pathway, involved in pancreas 
development and nervous system differentiation. Current studies suggest that the Ngn3 
transcription factor is the precursor to endocrine cells, which aids in cell elongation and 
cell growth (Bai et al., 2012).  Inhibition of the Ngn-NeuroD cascade has been shown to 
prevent premature differentiation of endocrine cells (Jensen et al., 2000). More specifically, 
this 2000 study looked into Notch1 and its ability to inhibit this cascade (Jensen, et al., 
2000). This is an example of dysregulation of the Ngn-NeuroD pathway, which has been 
confirmed to inhibit differentiation and cause loss of function in pancreatic alpha/beta-
cells. 
With respect to the GLUT pathway discussed above, some scientists believe that a 
disruption of insulin signaling results from chronic long-term ER stress in cells that use 
glucose, resulting in a lack of sensitivity to insulin and a lack of GLUT placement on the 
cell surface (Ozcan et al., 2004; Nakatani et al., 2005).  Chronic ER stress stems from the 
increased cellular demand for insulin, which results in increased insulin production. 
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Treatment with chaperone proteins that help alleviate ER stress has been tested in diabetic 
patients.  The cell’s unfolded protein response (UPR) aims to halt protein translation, 
degrade misfolded proteins, and activate signaling pathways that activate chaperone 
proteins. Chemical chaperones that lower ER stress were found to restore insulin sensitivity 
and glucose homeostasis in a mouse model of T2D (Ozawa et al., 2005; Ozcan et al., 
2006).  Other scientists have shown that obesity (that strongly correlates with T2D) is 
associated with ER inflammation.  Inflammation activates the c-Jun N-terminal kinase 
(JNK) and inhibitory kappa-B kinase (IKK) signaling pathways, leading to insulin 
insensitivity, lack of GLUT up-regulation, and hyperglycemia (Wellen and Hotamisligil, 
2005). 
With respect to the SERCA3 pathway discussed above, some scientists believe that 
disruption of Ca2+ signaling in pancreatic cells leads to reduced insulin secretion and T2D 
(Borge et al., 2002; Liang et al., 2014; Gilon et al., 2014).  This MQP project focuses on 
the SERCA3 pathway, which is an important signaling pathway in Ca2+ signaling.  This 
pathway appears to be affected in T2D. However, it is unclear whether the down-regulation 
of SERCA3 is a cause or consequence of the disease, or whether an irregular level of 
SERCA3 in humans affects physiological health (Zarain-Herzberg et al., 2014). 
A functional homeostatic system requires all hormones to work optimally and have 
the capability to adjust and accommodate changing levels of stress.  Any decrease in the 
system activity can result in possible system failure. Such physical changes may include: 
lower levels of alpha/beta islet cells, lower levels of insulin, and unregulated levels of 
glucose. These changes initiate the development of T2D. Short-term insulin treatment has 
been shown to cause a rise in Ca2+ levels and to stimulate insulin secretion in pancreatic β-
cells (Xu et al., 2000). However, in the long term, insulin treatment for diabetic patients 
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causes a sustained increase in calcium, enhanced glucose-stimulated insulin secretion, and 
no successful increase in insulin levels. Early in T2D patients, pancreatic β-cells secrete 
more insulin to compensate for insulin resistance, but this results in hyperinsulinemia 
(excess insulin relative to glucose). Eventually, β-cell functioning deteriorates and can no 
longer compensate for the insulin resistance. Unfortunately, research has not determined 
which event occurs first, or what the progressions of these consequences are in vivo. 
There is extensive research being done in the Program of Molecular Medicine at 
the University of Massachusetts Medical School in order to understand the mechanisms 
and pathways involved in T2D. Our mentor, Dr. Agata Jurczyk, focuses her research on 
the mechanisms of insulin secretion in pancreatic β-cells. The lab at UMMS has published 
numerous articles relating to T2D and its signaling pathways. Findings from the lab have 
provided evidence that human beta cells can proliferate under high glucose conditions; 
therefore, it is not the inability of human beta cells to proliferate that may lead to T2D but 
rather some other restriction that results in reduction of beta cell mass (Diiorio et al., 2011). 
It is important to note that in numerous experiments models of increasing rodent β-cell 
proliferation were often much more successful than human β-cell proliferation (Jurczyk et 
al., 2014). These experiments provide evidence that β-cells proliferate differently across 
species, and that diseases develop differently across species as well. However, animal 
models are still useful to study the progression of the disease including the onset and early 
development that is often impossible to study in people because we cannot predict when 
an individual will develop T2D. 
Perhaps some of the most relevant and significant contributions include the 
discovery of improved function and proliferation of adult human β-cells in diabetic mice 
treated with alogliptin (Jurczyk et al., 2013). The insulin level in treated cells was about 10 
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times greater than in the control, which is consistent with the increase in human β-cell 
proliferation with alogliptin treatment and increased insulin secretion. Another discovery 
made by this lab is the relationship between individuals with schizophrenia and their higher 
rates of contracting T2D than the general population (Jurczyk et al., 2015). A final relevant 
contribution of the lab is the discovery of the absence or disorganization of cilia in 
pancreatic islets can lead to dysregulated insulin secretion, which may contribute to 
diabetic symptoms (Diiorio et al., 2014; Harris, 2013). 
 
TCP-1 and CCT 
        While the focus of this project analyzes the role of the SERCA3 pathway and its 
implications in the development of diabetes, there are many other pathways involved in 
proper cell functioning such as protein folding. TCP-1 is one such pathway; impaired 
function of the TCP-1 chaperone protein may be linked to impaired function of insulin 
secretion. This presents the possibility that down-regulation of the TCP-1 pathway, like the 
SERCA3 pathway, may contribute to development of T2D.  One of the functions of 
chaperone proteins in the cell is to help correctly fold proteins inside the ER.  The T-
Complex Protein-1 (TCP-1) is encoded by gene tcp-1 located on the long arm of 
chromosome-6 (Fonatsch et al., 1987; Willison et al., 1987).  TCP-1 is a member of the 
chaperonin containing TCP1 complex (CCT), also known as the TCP1 ring complex 
(TRiC). This complex consists of two identical stacked rings, each containing eight 
different proteins (Figure-3). 
 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3:  Diagram of the CCT Complex.  Shown are the surface properties of protein TRiC 
(panel A) compared to similar proteins thermosome (panel B) and GroEL-GroES (panel C).  Blue 
represents positively charged patches, red negatively charged patches, and white neutral patches. 
Panels D-F denote the inner wall surface properties of the same respective proteins.  Blue denotes 
hydrophilic side chains, and yellow denotes hydrophobic side chains.  Figure is from: Cong et al., 
2010. 
 
Unfolded polypeptides enter the CCT central cavity and are folded in a process 
dependent on ATP. CCT aids in protein folding and inhibits protein aggregation 
(Slavinotek et al., 2001). Many chaperone proteins are operated in an ATP-dependent 
manner which allows for the regulated binding and folding of native and synthesized 
proteins such as: actin, tubulin, and myosin (Slavinotek et al., 2001; NCBI TCP1 t-
complex, 2016). Protein folding is critical for cell function because misfolded proteins 
cannot function optimally. Protein aggregation can also inhibit hormonal secretions by the 
cell. 
An impaired loss of function of chaperone proteins may be responsible for diseases 
such as Bardet Biedl Syndrome (BBS). In this case, a lack of appropriate protein folding 
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results from incorrect assembly of the BBS-2 subunit of the “BBSome” chaperonin itself 
(Harris, 2013). BBSomes are chaperone proteins that interact with leptin receptors, a 
hormone receptor involved with body weight regulation (Seo, et al., 2010). Although no 
work has currently found a direct link to BBSomes and T2D, a prediction can be made that 
impaired function of TCP-1 chaperone protein might be linked to an impaired function of 
insulin secretion. Impaired chaperone function leads to BBS, and patients share many 
symptoms with those of T2D patients (Harris, 2013). Previous research has shown that the 
knockdown of the BBS2 subunit gene in mice significantly lowers chaperone protein 
function as well as the ability to recover from an elevated glucose challenge (Harris, 2013). 
CCT belongs in the Group II category of chaperonin proteins. Unlike Group I 
chaperonins, the entire complex of Group II chaperonins usually contains two stacked, 
octa- or nonameric rings and six to nine different subunits (Slavinotek et al., 2001). This 
category of chaperone proteins are defined as regulator proteins that function without the 
use of a co-chaperone, such as GroES, which in prokaryotes works in conjunction with 
GroEL. Eukaryotes share a parallel to Group-I chaperone proteins with prokaryotes, 
existing as Hsp10 with Hsp60 within eukaryotic organisms (Slavinotek et al., 2001). Co-
chaperones function to cap the protein at the apical domain in the complex during protein 
folding (Chen et al., 2011). This cap is important in Group I chaperone proteins in order to 
maintain a highly basic microenvironment for the protein to be forced into its native 
conformation. However, Group II chaperone proteins that do not operate with a closely 
related co-chaperone. In place of a co-chaperone, this group of chaperones instead uses a 
helical protrusion above the apical domain that essentially performs this same function 
(Chen et al., 2011). 
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It is important for scientists to understand the functions of various CCT subunits, 
because small molecular changes can lower CCT chaperone function and lower hormonal 
secretion. Previous research has been done on the CCTβ subunit in mice (CCT complex, 
subunit 2 / subunit β) as well as CCTδ subunit in yeast (CCT complex, subunit δ / subunit 
4), and have concluded that both of these subunits can affect cell contractility, proliferation, 
migration of F-actin, and also induce conformational shifts within the CCTδ apical domain, 
respectively (Chen et al., 2011; Spiess et al., 2015). Changes within the apical domain in 
subunit CCTδ in yeast has been shown to disrupt the allosteric function of CCT ATPase, 
disrupting the binding ability within both the equatorial and substrate-binding domains of 
the CCT complex altogether (Spiess et al., 2015). 
 
SERCA3 and Type-2 Diabetes 
Sarco(endo)plasmic reticulum Ca2+ transport ATPase-3 (SERCA3) is the main 
pathway examined in the experiments of this MQP project. SERCA’s are a family of 
ATPases (SERCA-1, 2, 3) expressed in pancreatic islets.  SERCA’s are intracellular pumps 
located in the sarcoplasmic or endoplasmic reticulum of cells.  In muscle cells, SERCA3 
uses ATP to help move Ca2+ from the cytosol to the sarcoplasmic reticulum lumen, and 
sequesters Ca2+ during muscular contraction (Dode et al., 1996). In pancreatic cells, 
immunocytochemistry showed that SERCA3 is restricted to β-cells in the mouse pancreas 
(Arredouani et al., 2002).  The same researchers used SERCA-knockout mice to study β-
cell cytosolic free Ca2+, insulin secretion, and glucose homeostasis. SERCA knockouts 
showed that SERCA2b, but not SERCA3, is involved in basal Ca2+ regulation in β-cells, 
and SERCA3 functions in Ca2+ oscillations in response to glucose. However, their data 
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showed that a lack of SERCA3 by itself is insufficient to alter glucose homeostasis or 
impair insulin secretion in mice (Arredouani et al., 2002). 
Because SERCA3 alters cytoplasmic Ca2+ beyond background levels in response 
to glucose, loss of SERCA3 may contribute to T2D.  The secretion of insulin from 
pancreatic β-cells is dependent upon Ca2+ levels (Varadi et al., 1999), and disrupted Ca2+ 
homeostasis has long been established as a hallmark of diabetes. Thus, mutations within 
the gene encoding SERCA3 might weaken the β-cell’s response to glucose, and may 
contribute to diabetic symptoms. In contrast to the mouse KO study discussed above that 
showed no alteration in insulin secretion in KO mice (Arredouani et al., 2002), other 
scientists have shown that SERCA3 ablation decreases glucose-induced insulin release, 
which would logically contribute to diabetic symptoms (Ravier et al., 2011). Impaired 
SERCA3 function has previously been correlated with β-cell apoptosis in experiments 
using diabetic animal models (Varadi et al., 1999). And it has previously been shown that 
down-regulation of SERCA3 can affect calcium homeostasis in pancreatic β-cells, which 
impairs normal insulin secretion (Zarain-Herzberg et al., 2014). Most importantly, Varadi 
et al. (1999) identified four rare missense mutations in exons 4, 14, and 15 in the SERCA3 
gene of T2D patients with marked hyperglycemia and β-cell dysfunction. They concluded 
that in white Caucasians, the SERCA3 locus might contribute to the genetic susceptibility 
to T2D. 
However, it is currently unknown if SERCA3 down-regulation is a cause or an 
effect of the development of T2D. The lab at UMMS identified a significant 
downregulation (p = 0.0071) of SERCA3 in beta cells from T2D patients compared to 
healthy patients. Thus, the SERCA3 encoding exons become excellent candidates to 
attempt to correlate mutations with pancreatic β-cell defects. For these reasons, our 
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experiments were designed to test the effects of knocking down SERCA3. Specifically, the 
knockdowns were performed for the ATP2A3 gene. Genes ATP2A 1-3 encodes 11 
different isoforms of the SERCA pumps.  More specifically, gene ATP2A3 encodes 
isoforms SERCA3 a-f through alternative splicing (Zarain-Herzberg et al., 2014). SERCA3 
isoforms are present in hematopoietic cell lines, which give rise to all other blood cells, 
while SERCA2b and SERCA3 are the main isoforms present in pancreatic β-cells. 
Previous experiments have shown that impaired glucose-stimulated insulin secretion is 
associated with reduced expression of isoforms SERCA2b and SERCA3 (Zarain-Herzberg 
et al., 2014). Thus, down-regulation of these pathways may affect Ca2+ homeostasis in 
pancreatic β-cells and impair insulin secretion. Previous studies have also shown that 
improved glucose homeostasis is correlated with up-regulation of several islet genes 
including ATP2A3 (encoding SERCA3 isoforms a-f), indicating that mutations in those 
proteins could cause a lowering of insulin secretion due to changes in Ca2+ regulation 
(Zarain-Herzberg et al., 2014). This is important because alteration in Ca2+ regulation is 
often seen in heart failure, one of the leading causes of death in diabetic patients. Much 
remains unknown regarding early changes in Ca2+ regulation in a diabetic heart, but it has 
been shown that exercise improves sarcoplasmic reticulum Ca2+ regulation through the 
SERCA pathway, thus showing that lifestyle choices can have an impact on diabetes 
(Zarain-Herzberg et al., 2014). 
Another very similar pathway to SERCA3 is the Ca2+ transport ATPase isoform 
SERCA2b. Down-regulation of SERCA2b has also been shown to affect calcium 
homeostasis in pancreatic β-cells, which would in turn impair normal insulin secretion. 
Notably, SERCA2b has a reputation of being more sensitive to calcium than its cousin 
SERCA3. However, specific mutations in exons 4, 14, and 15 of SERCA3 have been 
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shown to be present in T2D patients (Varadi et al., 1999) and mutations in exon-4 have 
been shown to affect transitions during the calcium transport cycle (Zarain-Herzberg et al., 
2014), so it is possible that SERCA3 is more important in human than in rodent models 
and our project will focus on SERCA3. Prior to this project, as mentioned above, proteome 
studies of healthy and T2D patients’ beta cells detected significant downregulation of 
SERCA3 in T2D patients (Jurczyk et al., unpublished data). In any case, an increased 
understanding of the various SERCA isoforms is generally important. 
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PROJECT PURPOSE 
As discussed in the Background section, scientists believe that disruption of 
chaperone function or intracellular Ca2+ levels in pancreatic cells may lead to reduced 
insulin secretion and type-2 diabetes (T2D). This MQP project focuses on one protein that 
may be important to insulin secretion, regulation, and hormonal resistance: 
SERCA3.  SERCA3 is localized in pancreatic β-cells and is known to help regulate 
intracellular levels of Ca2+.  This protein appears to be diminished in T2D patients, but it 
is unclear whether its down-regulation is a cause or consequence of the disease.  Our 
project aims to confirm a decreased expression of SERCA3 in human T2D pancreatic 
samples relative to healthy controls, and to create a knockdown of the SERCA3 gene in 
human pancreatic cells to help determine whether its lack of functions may cause any 
intracellular physiological change. 
The knockdowns will be accomplished by Adenovirus using RNAi technology in 
EndoCβH-1 human pancreatic cell lines and stem cell derived human pancreatic beta cells, 
and verified by techniques such as western blotting, immunofluorescence imaging, and 
qRT-PCR.  We will also determine the role of SERCA3 in pancreatic beta cells. Finally, 
we will determine levels of insulin and SERCA3 expression in order to compare the 
differences of SERCA3 in healthy and T2D patients. 
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METHODS 
Selection of Human Pancreatic Tissue nPOD Samples 
The human pancreatic tissues used in this project were graciously provided to our 
group by the Department of Pathology at the University of Florida, and are a part of the 
Network for Pancreatic Organ Donors with Diabetes (nPOD) (www.jdfrnpod.org). 
Samples were chosen based on several factors, including the patient’s age, BMI, and 
phenotype (Healthy or T2D). The healthy samples chosen for the control group were 
specified to be within a similar age group of 20-24 years and BMI range of 20.7-22.6, but 
with varying race and gender. There is more variance in age and BMI values in the 
experimental group due to the greater range in differences that exist among diabetic 
patients. The T2D samples chosen for the experimental group ranged from 45-57 years, 
with a BMI range of 28.1-30.4. 
 
Table 1: Characterization of Healthy Control Pancreatic Tissues 
Based on Age, Sex, Race, and BMI. 
 
 Controls: Healthy 
Age Sex Race BMI 
6001 22 M Caucasian 21.9 
6029 24 F Hispanic 22.6 
6179 22 F Caucasian 20.7 
6235 23 M African American 22.3 
6238 20 M African American 21.7 
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Table 2: Characterization of Diabetic Experimental Pancreatic Tissues 
Based on Age, Sex, Race, and BMI. 
 Experimentals: Type-2 Diabetic 
Age Sex Race BMI 
6127 45 F Caucasian 30.4 
6147 47 M Hispanic 29.8 
6199 53 M African American 29.6 
6255 55 M Caucasian 29.4 
6272 57 F African American 29.6 
6277 48 M African American 29.5 
6280 47 M African American 28.1 
6283 56 F Caucasian 28.1 
 
 
13 nPOD samples were used throughout the experiments of this project, 5 of which 
were from healthy individuals, and 8 of which were from Type-2 diabetic patients. This 
ensured that the total sample sizes used to collect experimental results were big enough to 
conduct viable T-tests. 
 
Human β-Cell Growth, Fixation, and Staining 
EndoC- βH1 Human Beta Cells were supplied by Endocells, and were grown in 
DMEM Low Glucose media (Life Technology, Cat.#11885-084) supplemented with 
Sodium Selenite (6.7 µg/mL), Transferrin (5.5 mg/mL), Nicotinamide (1.2 g/mL), 
Albumin (10 g), and BME (1.75 µL into 500 mL media) according to the Endocells 
protocol (Paris, France). The coverslips and culturing dishes were coated with coating 
media DMEM High Glucose (Life Technology, Cat. #11965-092) and supplemented with 
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ECM (Sigma-Aldrich®, Cat. #E1270), Pen-Strep, and Fibronectin from bovine plasma 
(Sigma-Aldrich®, Cat. #E1270). The cells were split and passaged every 2 weeks and the 
media was changed once a week. 
For immunofluorescence, the cells were fixed in 4% paraformaldehyde for 10 
minutes at room temperature. Fixed coverslips were first washed with 1x PBS Solution 
(Life Technologies, Cat.#14190-144) and blocked in custom-made PBS-AT Solution using 
500 mL PBS, 10g BSA, and 12.5 mL 20% Triton X-100. Two 15-minute blocks of PBS-
AT were performed. Primary antibodies were diluted as follows: rabbit anti-human 
SERCA3 ATPase IgG (1:250) (ProteinTech, Cat. #13619-1-AP) or mouse anti-SERCA3 
ATPase (1:100) (Abcam, Cat. #ab54876), guinea pig anti-human Insulin IgG (1:250) 
(Abcam, Cat. #GR185515-2), and rabbit anti-glucagon IgG (1:100) (Abcam, Cat. #ab8055) 
in PBS-AT. Primary antibody incubation was performed at room temperature for 1 
hour.  After this hour, the coverslips were washed ten times with the PBS-AT solution. The 
secondary antibodies were diluted as follows: anti-mouse Alexa 596 (1:1000) (Invitrogen, 
Cat. #A11029) or anti-rabbit Alexa 488 (1:1000) (Invitrogen, Cat. #A11034), and anti-
guinea pig Alexa 610 (1:500) (Invitrogen, Cat. #A21450) in PBS-AT. The secondary 
antibody incubation was run for 1 hour at room temperature. After the incubation, 5 washes 
of PBS-AT and 5 washes of PBS were performed. The coverslips were mounted in Prolong 
Gold with Dapi (Life Technologies, Cat. #P36935). One drop was placed onto each slide 
before the coverslip was mounted cell side down. The slides with coverslips were left in 
the dark to dry overnight at room temperature, and then rimmed with nail polish. These 
coverslips were imaged for immunofluorescence using the Nikon Eclipse Ti Microscope 
and Nikon Elements Analysis software. 
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qRT-PCR 
qPCR was conducted to assess the expression of mRNA within each of the samples. 
The RNA within each sample was isolated from harvested cells, pelleted, and lysed in 700 
µl QIAzol Lysis Reagent (Qiagen). RNA from human islets and cell lines was prepared 
using a Qiagen RNEasyⓇ Mini Kit (Cat. #74104 & 74106). The isolation was performed 
according to manufacturer instructions. The samples were stored at -80ºC. The 
concentration and quality of RNA was determined using the Bioanalyzer at UMass Medical 
School Core Facility. 
        To prepare cDNA, SuperScript ViLo Master Mix was used to generate cDNA from 
the isolated RNA (Invitrogen, Cat. #11755-050). The isolated cDNA was used to perform 
qPCR for the gene of interest using a Taqman Probe Assay. For SERCA3, a probe was 
used for the gene ATP2A3 (Applied Biosystems, Cat. #hs00193090). Actin was used as a 
control (Applied Biosystems, Cat. #hs01060665). 
 
Viral Knockdowns and Cell Culturing 
Adenoviral mediated knockdowns using RNAi technology were performed using 
EndoC βH-1 human pancreatic cells, as well as stem cell derived human β-cells from 
Melton Lab (Pagliuca et al., 2014). EndoC βH-1 Human Pancreatic Cells were grown in 
cultures for a minimum of 2 weeks to reach the desired confluence and cell count. Media 
were changed once a week to encourage cell growth by removing 10 mL of the growth 
medium and replacing it with 10 mL of pre-warmed, fresh growth medium. The stem cell 
derived β-cells were generously provided by Melton Lab (Harvard University). 
For Adenoviral knockdowns, the cells were plated on 6-well well plates or 
coverslips, and infected with 50, 100, or 200 MOI of appropriate adenovirus. Adenovirus 
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infection was performed for 48 and 72 hours to determine maximum knockdown efficiency 
for SERCA3. The adenovirus SERCA3 construct and GFP control were purchased from 
Vigene. To determine infectivity of the virus, each construct expressed GFP to mark 
infected cells. Following infection, the cells were harvested for Western analysis and qPCR 
to determine knockdown efficiency, and coverslips were fixed for imaging. In addition, the 
stem cell derived beta cells were used for perfusion to determine the effect of knockdown 
on insulin secretion. 
 
Immunofluorescent and Immunohistochemistry Staining 
        nPOD pancreatic tissues were stained by the Cell Morphology Core Facility at 
UMass Medical School. The Nikon Eclipse Ti Microscope was used to view the stained 
cells at a total magnification of 20x; which were selected for further observation and 
analysis. To accurately separate the view of the different proteins of interest in each image, 
four different filters were chosen: Dapi (Blue), FitC (Green), MCherry (Red), and Cy5 (Far 
Red). The fluorescence mean intensities were obtained and analyzed using Nikon Elements 
Analysis software. Exposure times were kept constant between samples in order to 
compare the intensities. Dapi was used as control for staining quality of samples and to 
normalize the mean intensities of light from the FitC and Cy5 filters. Approximately 10 
islets were chosen from each pancreatic tissue sample. 
Quantitative analysis was done in Microsoft Excel to compare overall fluorescence 
intensity values for each filter. The FitC (SERCA3) and Cy5 (Insulin) were normalized to 
Dapi and a ratio was obtained for the average intensity of Fitc/Dapi and Cy5/Dapi. This 
data was used to extrapolate differences in levels of Insulin and Serca3 in healthy and T2D 
patients. 
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Western Blotting 
Cells were harvested using a cell scraper in 100-200 µL of RIPA Lysis buffer 
(Boston BioProducts, Cat. #bp-115) with Complete Mini protease inhibitor cocktail tablet 
(Roche Diagnostics, Cat. #11374600) and lysed in ice for 20 minutes with frequent 
pipetting. Protein concentration was determined using a Pierce® BCA Protein Assay Kit 
(ThermoScientific Cat. #23225) according to the manufacturer’s protocol. 10 µg of protein 
was loaded onto each well of 4-20% gradient gel and run at 100 volts for 15 minutes, and 
then up to 170 volts until completion. The gel was transferred for 2 hours at 100 volts onto 
a PVDF membrane. For transfer, the gel was equilibrated in transfer buffer. A “transfer 
sandwich” was prepared that contained filter paper, a PVDF membrane, and gel, and was 
cushioned by pads and pressed together by a support grid. Before assembly, the membrane 
was saturated with 100% methanol to wet the membrane and allow for appropriate transfer 
of the proteins. After assembling the sandwich, it was placed vertically in an 
electrophoresis tank between wire electrodes and filled with transfer buffer. To ensure that 
the gel would not overheat due to the high voltage passing through the apparatus, it was 
surrounded in an ice bath. 
After transfer, the membrane was blocked in 5% milk, followed by incubation with 
primary polyclonal antibodies: rabbit or mouse anti-human SERCA3 (1:500) (ProteinTech, 
Cat. #13619-1-AP), rabbit anti-human insulin (1:250) (Abcam, Cat. #ab7842), and mouse 
anti-human Actin (1:3000) (Abcam, Cat. #ab8055). The primary antibody incubated for at 
least 12 hours, but no more than 24 hours, at 4ºC. The secondary antibodies were: goat 
anti-rabbit-HRP IgG (1:3000) (Invitrogen, Cat. #A11034), and rabbit anti-mouse HRP IgG 
(1:5000) (Invitrogen, Cat. #A11061). Secondary antibody incubations were run 1-2 hours 
at room temperature. Milk was used to block with non-specific proteins. Membranes were 
 22 
developed using ECL Western Blotting Detection Reagent (Amersham, Cat. #9622301). 
The film was developed with varying exposure times that depended on the protein signals.  
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RESULTS 
 
The worldwide prominence of T2D has brought it the foreground of attention in the 
scientific community. T2D patients usually have insulin resistance, a lack of response to 
insulin, or lack insulin altogether, and tend to develop hyperglycemia. Although much 
research has focused on the mechanisms of insulin secretion, factors leading to insulin 
insensitivity are not fully understood. Insulin has been identified as the only hormone that 
lowers serum glucose levels in the body. When insulin binds to its target receptor, it 
initiates multiple signaling pathways that function in general gene expression, glucose 
metabolism, and protein synthesis. Disruption in these cell signaling pathways can result 
in glucose dysregulation, and thus, diabetes. One specific pathway that has previously been 
identified as important in Ca2+ signaling is the SERCA3 pathway.  This pathway appears 
to be down regulated in T2D, but it is not clear whether its down-regulation is a cause or 
consequence of the disease. Thus, the experiments in this project were performed to 
examine the role of SERCA3 in insulin secretion, and its plausible correlation with down-
regulation of insulin in T2D patients. 
We began by using a proteome analysis to validate previous literature that SERCA3 
protein is reduced in T2D patient Islets (N=9) compared to healthy controls (N=6) (Figure-
4).  The data show that SERCA3 protein is significantly reduced (p=0.0071) in T2D patient 
islets relative to healthy controls, and it supports and validates the previous findings. 
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Figure-4: Quantification of Normalized Intensities for Protein Expression of 
SERCA3 Levels in Healthy Individuals (N=6) Compared to T2D Individuals 
(N=9). Average intensities were calculated for Healthy: 1,485116833, and T2D: 
698,333,333. Statistical analysis gave a significant p-value of 0.0071. 
  
Human β-Cell Immunohistochemical Staining Shows Decreased of 
SERCA3 in T2D Patients 
 
        Immunohistochemical staining and microscopy was performed with insulin or 
SERCA3 antibodies in healthy or diabetic pancreas sections to determine protein levels of 
these two key proteins.  Pancreatic sections from normal or diabetic patients were stained 
and imaged using the Nikon Eclipse Ti Microscope (Figure 5). T2D patients had smaller 
islets, with significant down-regulation of insulin and SERCA3. Cell staining was 
performed using specimens from 5 (N=5) healthy patients, and 8 specimens (N=8) from 
T2D patients.  These qualitative beta cell staining results indicate that the levels of insulin 
and SERCA3 proteins are decreased in T2D patients. 
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Figure 5: Example Insulin and SERCA3 Immunohistochemical Microscopy on Healthy and 
T2D Patients.  Human pancreatic islet cells from healthy (upper row) or T2D patients (lower row) 
were stained using antibodies for insulin (left column) or SERCA3 (right column).   T2D islets 
show significant down-regulation of insulin and SERCA3 proteins.  This experiment was repeated 
several times, healthy N=5 and T2D N=8. 
 
 
Insulin and SERCA3 Immunofluorescence 
The down-regulation of SERCA3 observed with immunohistochemistry was 
further verified by immunofluorescence imaging (Figure-6).  The figure shows a typical 
islet image of Cy5 (red) (insulin), FitC (green) (SERCA3), and the overlay of both 
(yellow).  The healthy islet (upper row) is not morphologically compromised, and shows 
significant overlay of insulin and SERCA3. The T2D islet (lower row) is more dispersed, 
less concentrated, and the protein signals are reduced especially for SERCA3. 
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Figure-6:  Example Immunofluorescent Micrograph of SERCA3 and Insulin Protein Levels 
in Healthy and T2D Human Pancreatic Islets.  Dapi (blue) represents nuclei, Cy5 (red) denotes 
Insulin, and FitC (green) denotes SERCA3. T2D islets (bottom row) show lower levels of insulin 
and SERCA3 compared to control islets (top row). The overlay of insulin and SERCA3 appears 
normal in healthy islets, but with little to no overlap in T2D islets. 
 
A second immunofluorescent micrograph is shown in Figure 7 for one healthy 
sample and two T2D samples.  Again, strong correlations were observed between the FitC 
(SERCA3) and Cy5 (Insulin) staining in the control islet, while the equivalent staining in 
T2D islets is reduced, and not localized in the same regions. 
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Figure-7: A Repeat Immunofluorescent Micrograph of Healthy and T2D Human Pancreatic 
Islets Stained for Insulin and SERCA3.  Dapi (blue) stained nuclei, Cy5 (red) stained Insulin, 
and FitC (green) stained for SERCA3. T2D islets (bottom row) show lower levels of insulin and 
SERCA3 compared to control islets (top row). The overlay of insulin and SERCA3 appears normal 
in healthy islets, while little to no overlap (yellow) is present in diabetic islets. 
 
The SERCA3 and insulin protein levels were quantitated from the 
immunofluorescent micrographs.  Healthy individuals (N=101)  had an average mean 
intensity of 5544 intensity units for SERCA3, and 3317 intensity units for Insulin. T2D 
individuals (N=84) had an average mean intensity of 4099 intensity units for SERCA3 and 
2799 intensity units for Insulin. When normalized to Dapi, in order to adjust for differences 
in staining penetration and sample quality, the Healthy SERCA3/DAPI ratio was 1.812, 
compared to a T2D ratio of 1.218 (Figure-8).  The Healthy Insulin/DAPI ratio was 1.092, 
compared to a T2D ratio of 0.813 (Figure-9).  This data indicates that both SERCA3 and 
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insulin are lower in T2D patients compared to Healthy, and support the findings of the 
immunohistochemistry and western blots. 
 
Figure-8: Quantitative Summary of the SERCA3 Fluorescence Levels of Figure-7.  Shown are 
the mean intensity of SERCA3 levels (FitC) normalized to nuclei (Dapi) in T2D samples (red) and 
healthy samples (blue). The Healthy SERCA3/DAPI ratio is 1.812 ± 0.059, while the same ratio in 
T2D patients is 1.218 ± 0.053. 
 
 
 
Figure-9: Quantitative Summary of the Insulin Data from Figure-7.  Shown are the mean 
intensities of Insulin levels (Cy5) normalized relative to nuclei (Dapi), in diabetic samples (red) 
and healthy samples (blue). The mean Insulin/DAPI ratio in Healthy individuals is 1.092 ± 0.047, 
while the same ratio in T2D patients is 0.813 ± 0.035. 
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Taken together, the immunohistochemical and immunofluorescence data indicate 
that SERCA3 and Insulin protein levels are decreased in T2D samples compared to healthy 
individuals.  The total intensities of 101 Healthy and 84 T2D pancreatic islets were 
quantified from 5 Healthy and 8 T2D patients. Statistical two-tailed t-tests were then 
conducted.  The p value for SERCA3/DAPI, Healthy versus T2D, was 2.01 x 10-8, 
indicating that SERCA3 is significantly lower in T2D compared to Healthy patients.  The 
p value for Insulin/DAPI, Healthy versus T2D, was 6.26 x 10-3, also showing a significantly 
lower protein level in T2D patients.  
 
SERCA3 Western Blots 
 
To support the qualitative and quantitative findings of the immunofluorescence 
microscopy, SERCA3 western blots were performed to determine the protein levels 
(Figure 10). The western blot shows N=3 healthy samples compared to N=4 T2D samples, 
and again shows a reduction in T2D SERCA3 protein levels relative to healthy control 
protein levels. Huge differences of variability in levels of Actin and Insulin within just the 
T2D samples has led to problematic statistical analysis. Also, because the imaged bands of 
SERCA3, Insulin, and Actin were stitched together, each had a different background 
lighting, thus affecting the average band intensity of each sample. Because of this, the 
insulin signals were not quantified from this blot, but given the higher protein load for the 
two T2D lanes this indicates that insulin may also be reduced in the T2D samples. 
The data is quantified in (Table-4), and shows no significant correlation between 
SERCA3 and insulin bands from healthy and T2D patients. It is suspected that the huge 
variability in band intensity resulted in high deviations and a larger p-value. The actin 
bands indicate that the loading of each well was not equal, which is further proved by the 
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difference in Insulin levels between T2D samples 1 and 2, vs 3 and 4. With a p-value of 
0.1018, the data from Table 4 and the western blot in Figure 11 is statistically insignificant.  
 
Figure-10: Repeat SERCA3 and Insulin Western Blot Showing N=3 WT Samples and N=4 
T2D Samples.  Bands are shown for SERCA3 (top row), Insulin (middle row), and actin (lower 
row). Approximate band lengths are: SERCA3, 97 kD; Actin, 42 kD; Insulin, 6 kDa. 
 
 
Table 4: Mean SERCA3 Band Intensities from Figure-6 Blot. 
 
 Healthy 
Individuals 
T2D 
Patients 
Sample-1 123.73  98.28 
Sample-2 176.92 97.91 
Sample-3 163.16 105.48 
Sample-4  146.61 
Average SERCA3 Band 
Intensity Relative to Actin 
1.069 0.779 
STDev (%) 20.6% 19.8% 
Std. Err (%) 12.7% 7.7% 
P Value 0.1018 
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Adenoviral Knockdown Experiments for SERCA3 
 
In order to perform a knockdown of SERCA3 in pancreatic cells, EndoC-βH1 cells 
and human stem cell derived β-cells were infected with an adenovirus encoding a SERCA3 
shRNA.  The adenovirus also encoded green fluorescent protein (GFP) as a marker for 
infected cells.  Adenoviral infection was tested for several variables, including: length of 
incubation and titer of adenovirus.  The data indicated that SERCA3 islets were equally 
susceptible to infection by Adeno-GFP and Adeno-shRNA-GFP.  
 
 
Figure-11: Percent Infection of Pancreatic EndoC-βH1 Cells With Adenovirus.  The Adeno-
GFP signal shows the presence of adenoviral-infected cells. After 72 hours of infection, the cells 
show about 90% infection efficiency. 
 
 
 
 
 
Figure-12: Comparison of Infection Rates of EndoC-βH1 Cells with Adeno-GFP Control 
(Adenovirus encoding GFP but no snRNA) versus Cells Infected With Adenovirus-shRNA-
GFP (MOI of 200).  The green Adeno-GFP signal (left) shows the presence of GFP tagged cells. 
The Adeno-shRNA-GFP green signal (right) also shows the presence of adenoviral-infected cells. 
After 72 hours of infection, both the control and shRNA-infected cells show similar rates of 
infection. 
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The successfully infected EndoC-βH1 cells can then be used in future assays to 
perform further phenotypic analysis for SERCA3 and Insulin. 
qRT-PCR was conducted to assess the amount of SERCA3 mRNA present in 
control and experimental samples. Calculated mRNA levels for SERCA3 were determined 
in the EndoC-βH1 cells for both Adeno-GFP control (adenovirus encoding GFP but no 
shRNA) and the shSERCA3 (knockdown) samples. Differences in fold change between 
the two sample types can be seen below (Figure-14). The fold change was normalized to 
actin control and was assigned number 1.0 for the Adeno-GFP cells. A fold change of 
0.0625 was calculated for the shSERCA samples, an indicator of a successful knockdown 
of SERCA3 mRNA. Since there was only one sample, triplicate runs for qPCR could not 
provide statistical results, so this experiment needs to be repeated with additional samples 
in order to reach statistical significance.  
 
Figure-13: qRT-PCR Analysis of SERCA3 mRNA Levels for Adeno-GFP Control and 
Adeno-shSERCA3 Cells. qRT-PCR was conducted to quantify SERCA3 mRNA levels in our 
control and experimental samples (N=2). Fold changes were calculated for Adeno-GFP Control 
(1.00) and Adeno-shSERCA3 (0.0625).  
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SERCA3 Protein Knockdown 
 
A western blot was run to determine the SERCA3 protein levels in control and 
knockdown cells (Figure-14).  The figure shows a comparison of two control EndoC-βH1 
cell line lysates versus two shSERCA lysates immunoblotted for SERCA3 (top band), 
Actin (middle band), and Insulin (bottom band), whose identities were deduced using 
specific antibodies and from their known relative kD protein sizes: SERCA3, 97 kD; Actin, 
42 kD; Insulin monomer, ~6 kDa (Sen et al., 2002). It was quantified that slightly more 
actin was loaded into lanes 4 and 5, but those two samples still showed reduced SERCA3 
and insulin protein levels relative to control lanes 2 and 3.   
  
 
Figure 14: SERCA3 and Insulin Western Blot and Quantitation.  The left panel shows a 
SERCA3 western blot, and the right panel shows quantification of the SERCA3 bands relative to 
actin.  Blot lanes are: MW marker (lane 1), healthy controls (Lanes 2 and 3), and SERCA3 
knockdown experimental samples (Lanes 4 and 5).  Bands are SERCA3 (top), Actin (middle), and 
Insulin (bottom), identified by their expected MWs. The right panel shows a densitometer 
quantitation of the SERCA3 bands (N=2). Statistics was not applied to the plot, as it represents 
only two replicates. 
 
 
The mean intensities of the SERCA3 bands were quantitated by densitometry 
relative to actin, and are shown in the right panel of (Figure-14) and in (Table-
5).  SERCA3 protein levels were approximately 56.2% lower in SERCA3 knockdown 
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lanes compared to Adeno-GFP control.  Standard deviations were 31% and 22%, 
respectively, for control and shSERCA3. Standard error was 10.5% and 3.3%, respectively, 
for control and shSERCA3. The western data indicates that SERCA3 expression was 
reduced by the specific shRNAs. 
 
 
Table 5: Mean SERCA3 Band Intensity 
From Figure-14 Blot. 
 Control Knockdown 
Sample-1 40.94 29.67 
Sample-2 64.25 27.02 
Average SERCA3 Band 
Intensity Relative to Actin 
0.479599 0.210089204 
STDev (%) 14.8976 4.6933901 
Std. Err (%) 10.5342 3.318728 
P Value 0.0123 
 
 Statistical tests show significant differences in SERCA3 levels relative to actin in 
control samples versus knockdown samples. This data showing lower SERCA3 protein 
levels in Adeno-shRNA cells relative to Adeno-GFP cells supports the qRT-PCR data 
showing a similar result for SERCA3 mRNA. 
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DISCUSSION 
         
The findings of this project provide statistically significant evidence that SERCA3 
is down-regulated in T2D islets compared to healthy islets. This observation was consistent 
throughout immunohistochemical staining of pancreatic cells, western blots, and 
immunofluorescent microscopy.  For the latter assay, the reduction was validated as being 
statistically significant in a total of 185 samples (N=101 WT; and N=84 T2D). The reduced 
levels of SERCA3 in T2D patient islets supports previous research arguing that disruption 
of Ca2+ signaling in pancreatic cells can lead to reduced insulin secretion and diabetic 
symptoms (Borge et al., 2002; Liang et al., 2014; Gilon et al., 2014).  Previous work with 
diabetic mice showed an impaired SERCA3 function correlated with β-cell apoptosis 
(Varadi et al., 1999), and that down-regulation of SERCA3 can affect calcium homeostasis 
in pancreatic β-cells, which impairs normal insulin secretion (Zarain-Herzberg et al., 
2014). In addition, Varadi et al. (1999) identified four rare missense mutations in exons 4, 
14, and 15 in the SERCA3 gene of T2D patients with marked hyperglycemia and β-cell 
dysfunction. 
Several problems were encountered during this project.  One problem was the 
significant amount of time required for each experiment, from the initial culture of the cells 
to the final cell staining and signal analysis.  Planning several weeks in advance was 
required to ensure that all experiments could be achieved. In addition, some of the protocol 
details had to be worked out, such as the choice of primary antibodies used in the 
experiments, and the proper incubation times. Specifically, while performing Western 
analysis a rabbit anti-human SERCA3 ATPase IgG (1:100) primary antibody was used 
initially. Since the rabbit antibody is polyclonal, its binding affinity may not be as specific 
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as the monoclonal mouse anti-SERCA3 ATPase (1:100) antibody and both were run to 
verify results. However, the rabbit anti-human SERCA3 ATPase IgG (1:100) antibody 
worked better in immunofluorescent imaging, and so this antibody was used instead of the 
mouse anti-SERCA3 ATPase (1:100) antibody in experimental repeats. Quantification of 
data from immunofluorescent imaging relied on accurate selection of regions of interest in 
Nikon Elements Analysis software. Human error and variation also contributed to standard 
error of quantitative results during this process. Another complication of IF imaging was 
that the pancreatic tissues were not physically flat, so some parts of the islets remained out 
of focus when selecting for ROIs. These unfocused regions could affect the calculations of 
Insulin and SERCA3 mean intensities. 
Other complications aside from IF imaging include the membrane high background 
that was present in one of the Western Blots that was performed (Figure-11). Again, this 
may have caused discrepancies in the quantitative analysis of band intensities due to 
inconsistent background intensity or higher background intensity. The inconsistent loading 
as observed by unequal Actin (control) in the lanes may have skewed the quantification of 
SERCA3 and Insulin levels as well since the intensities were adjusted to the level of Actin. 
For this reason, this project included experimental repeats to minimize discrepancies due 
to human error and standard deviation.  
Several future experiments would nicely extend this preliminary project. Given the 
successful knockdown of SERCA3 by shRNA, shown by results of Western analysis and 
qRT-PCR, the next step in determining whether the SERCA3 pathway is required for 
optimal insulin secretion would be to assay insulin levels in the knockdown cells relative 
to controls using westerns and RT-PCR. Due to time restraints, the knockdowns were not 
optimized to minimize expression, and they were not analyzed for insulin secretion assays. 
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After using an adenovirus to perform knockdowns, a lentiviral knockdown system could 
then be used as a second method of verification. A lentiviral knockdown would provide 
additional information that an adenoviral knockdown could not. Adenoviral DNA does not 
integrate into DNA and therefore is not copied during cell replication; in contrast, lentiviral 
DNA is passed on during cell replication. Both knockdown systems could be compared for 
efficiency of knockown.  In addition, CRISPR technology, a novel technique used for 
efficient gene knockouts, could also be tested to alter the genome to eliminate the SERCA3 
gene. The gene removal could be verified by genomic PCR, and its effects on SERCA3 
expression measured by qRT-PCR and westerns. 
The next steps after a confirmed knockdown would be to test the effects of the 
knockdown on insulin secretion in vitro (by perfusion) and in vivo (by transplantation). 
These techniques would help determine whether any change in hormonal levels are a cause 
or consequence of SERCA3 knockdown. For instance, if insulin secretion was lowered by 
a SERCA3 knockdown, then this provides evidence that the SERCA3 metabolic pathway 
is required for optimal insulin secretion and could relate to the pathogenesis of T2D. 
However, if insulin secretion was not lowered in knockdown cells, then this provides 
evidence that optimal insulin secretion does not require proper functioning of the SERCA3 
metabolic pathway and that downregulation of SERCA3 must be a consequence of the 
pathogenesis of T2D. 
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